OBJECTIVE: Although spontaneous abortion (SAB) is common, recurrent SAB is far less common, with only 2-3% of women having 2 consecutive SABs and <1% having 3 or more consecutive SABs. Although the incidence of subsequent SAB has been well-defined in women with a history of recurrent pregnancy loss (RPL), prior studies evaluating perinatal outcomes in subsequent pregnancies have shown mixed results. In this study, we aimed to evaluate perinatal outcomes in our patient population in women with a history of RPL. STUDY DESIGN: Retrospective cohort study of singleton, non-anomalous gestations at 20 weeks who delivered at our academic institution. The exposed group was defined as women with a history of 2 consecutive SABs at <12 weeks. These women were compared to women with a history of 1 SAB at <12 weeks. The primary outcome was preterm birth at <37 weeks. Secondary outcomes included fetal growth restriction (FGR), gestational diabetes (GDM), hypertensive disorders of pregnancy, indication for preterm birth, gestational age (GA) at delivery, fetal demise, cesarean delivery, and a composite of neonatal complications (Apgar <5 at 5 minutes, perinatal death, and NICU admission). Multivariable logistic regression was performed to adjust for confounders, with the following variables considered in the model: maternal age, race, BMI, payor status, hypertension, and diabetes. RESULTS: Of 17,670 women included, 235 (1.3%) had a history of 2 consecutive SABs. Compared to women with a history of 1 SAB, women with RPL were not more likely to have a preterm birth (Table) . However, these women were more likely to have FGR (6% vs 2.4%,p¼<0.001, AOR 2.1, 95% CI: 1.1-3.8) and gestational DM (12.3% vs 6.6%, p¼<0.001, AOR 1.59, 95% CI: 1.04-2.43). All other maternal and neonatal outcomes were not statistically different. CONCLUSION: Women with a history of 2 consecutive SABs have an increased incidence of FGR and GDM in a subsequent pregnancy. Monitoring for these conditions in women with 2 consecutive SABs may be warranted. Georgetown University School of Medicine, Washington, DC OBJECTIVE: To identify the blood loss measurement technique that best predicts need for red blood cell (RBC) transfusion after cesarean delivery (CD) and to define the amount of blood, by technique, that predicts RBC transfusion. STUDY DESIGN: This was a retrospective review of a quality improvement initiative of all women with singleton pregnancies who underwent CD at >¼34 weeks' gestation between July 1, 2017 and June 30, 2018 at MedStar Washington Hospital Center. Women were eligible to have blood loss measured by visually estimated blood loss (EBL), gravimetric quantitative blood loss (QBL), Gauss Surgical's Triton ipad application (TBL) and a 24-hour postoperative complete blood count evaluation. Women with multifetal gestation, hypertensive disease and magnesium or anti-hypertensive treatment were excluded. The primary outcome was RBC transfusion. Receiveroperating characteristic curves with area under the curves (AUC) for RBC transfusion by blood loss measurement techniques were created by EBL, QBL and TBL. Blood loss volumes that best predict RBC transfusion were estimated according to blood loss measurement techniques. The secondary outcome included blood loss volumes that best predict RBC transfusion as estimated by measurement technique. We performed a secondary analysis after excluding women with preoperative hemoglobin <10 g/dL. RESULTS: Of the 444 women meeting inclusion criteria, 21 (4.7%) received RBC transfusion. Women who received RBC transfusion compared to women without RBC transfusion were more likely to have higher gravidity, intravenous fluid infusion, EBL, QBL, TBL, and lower preoperative hemoglobin levels (all P <.05). 
Georgetown University School of Medicine, Washington, DC OBJECTIVE: To identify the blood loss measurement technique that best predicts need for red blood cell (RBC) transfusion after cesarean delivery (CD) and to define the amount of blood, by technique, that predicts RBC transfusion. STUDY DESIGN: This was a retrospective review of a quality improvement initiative of all women with singleton pregnancies who underwent CD at >¼34 weeks' gestation between July 1, 2017 and June 30, 2018 at MedStar Washington Hospital Center. Women were eligible to have blood loss measured by visually estimated blood loss (EBL), gravimetric quantitative blood loss (QBL), Gauss Surgical's Triton ipad application (TBL) and a 24-hour postoperative complete blood count evaluation. Women with multifetal gestation, hypertensive disease and magnesium or anti-hypertensive treatment were excluded. The primary outcome was RBC transfusion. Receiveroperating characteristic curves with area under the curves (AUC) for RBC transfusion by blood loss measurement techniques were created by EBL, QBL and TBL. Blood loss volumes that best predict RBC transfusion were estimated according to blood loss measurement techniques. The secondary outcome included blood loss volumes that best predict RBC transfusion as estimated by measurement technique. We performed a secondary analysis after excluding women with preoperative hemoglobin <10 g/dL. RESULTS: Of the 444 women meeting inclusion criteria, 21 (4.7%) received RBC transfusion. Women who received RBC transfusion compared to women without RBC transfusion were more likely to have higher gravidity, intravenous fluid infusion, EBL, QBL, TBL, and lower preoperative hemoglobin levels (all P <.05). volumes that best predict RBC transfusion by EBL, QBL and TBL are 850 mL, 915 mL, and 643 mL, respectively, with high sensitivity and specificity (Table) . After excluding women with preoperative hemoglobin <10 g/dL, the results remained consistent. CONCLUSION: Blood volume predictive of RBC transfusion in women with CD was dependent on the measurement technique used and did not reflect standard blood loss criteria for postpartum hemorrhage (PPH). PPH defined by >1000 mL of blood loss may underestimate the need for transfusion for some women undergoing CD.
Very advanced maternal age and perinatal outcomes
Elizabeth A. Hoover, Jerome Yankowitz, Judette Louis University of South Florida Morsani College of Medicine, Tampa, FL OBJECTIVE: The term advanced maternal age (age35, AMA) does not account for the continuum of AMA. We studied differences in obstetric outcomes among women of younger advanced maternal age (age 35-44, YAMA) as compared to those of very advanced maternal age (age45, VAMA). STUDY DESIGN: We conducted a retrospective cohort analysis of women delivering at a single tertiary care center between January 2013 and June 2018. Three groups were compared based on age at delivery (age 35-39 YAMA1, 40-44 YAMA2, and age45 VAMA). Clinical charts were reviewed for relevant maternal comorbidity including hypertension and diabetes, medical management, and maternal and neonatal outcomes. Data were analyzed using chisquare, student t-test, and logistic regression analyses where appropriate, and p-value <.05 was statistically significant. RESULTS: Of the 30,983 deliveries during the study period, 5101 women were identified as AMA for a prevalence of 164 per 1000 births. Compared to YAMA1 (n¼4081) and YAMA2 (n¼926), the VAMA (n¼94) group was similar in race, ethnicity, insurance status, and obesity. The VAMA group had the lowest rate of comorbidity compared to YAMA1 and YAMA2 (7 vs 10 and 14%, p¼.002). The groups were similar in the rates of intervention for abnormal fetal surveillance (2.1 vs 2.7 and 2.7%, p¼.94). VAMA was associated with more cesarean delivery, preterm birth (42.6 vs 14.6 and 17.2%, p<.001), and very preterm birth (11.7 vs 3.5 and 3.7%, p<.001). Accordingly, VAMA was also associated with a higher rate of NICU admission and very low birthweight compared to YAMA1 and YAMA2. No difference in stillbirth rate was found between groups (0 vs 0.5 and 0.5%, p¼.72). After controlling for confounding variables, maternal age (per year) [OR 1.089; 95%CI 1.05-1.1] and comorbidity [OR 4.67; 95%CI 2.2-9.5] were associated with preterm birth but not obesity. CONCLUSION: Very advanced maternal age is associated with more preterm birth, but comorbid conditions appear to be the primary driving factor. This information may assist in directive counseling of women who desire pregnancy at advanced ages. 
OBJECTIVE:
The Ex-Utero Intrapartum Treatment (EXIT) procedure is used to secure the airway for fetuses with prenatally diagnosed airway obstruction prior to postnatal life. Because EXIT is performed under deep maternal general anesthesia for uterine relaxation, and because of prolonged uterine distention from polyhydramnios, EXIT carries a higher risk profile than routine cesarean section. We describe here the obstetrical course, and maternal outcomes of a series of patients with fetal neck mass delivered via EXIT. STUDY DESIGN: Retrospective chart review of patients delivered between January 2001 and April 2018 in our tertiary referral fetal center. Outcome variables included gestational age (GA) at delivery, polyhydramnios, need for emergency EXIT, preterm premature rupture of membranes (PPROM), placental location, maternal estimated blood loss, transfusion requirements, and length of hospital stay. Data were tested for normality and reported as median [range] and n (%). RESULTS: A total of 21 patients delivered by EXIT were evaluated (fetal indication: lymphatic malformation, n¼10 and teratoma, n¼11). The median EGA at the time of diagnosis and delivery were 20 [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] and 36 [30] [31] [32] [33] [34] [35] [36] [37] [38] weeks, respectively. 17(81%) of the patients developed polyhydramnios at a median GA of 30 [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] weeks, of whom 10 (58.8%) underwent amnioreduction. 9 (42.9%) of the EXIT procedures were performed emergently, 5 (23.8%) being for PPROM. Maternal estimated blood loss was 1000 [500-2000] mL; 7 (33.3%) patients received a blood transfusion. The median maternal hospital stay was 4 [4-10] days. The table shows the demographics and obstetric outcomes of the study subjects. CONCLUSION: Even with full preparedness 40% of our EXIT cases were emergent, highlighting the need for an experienced and prepared multidisciplinary physician and nursing team capable of rapid deployment. Even with such a team one third of our patients required a blood transfusion during or after her EXIT procedure, highlighting the risks of this type of delivery. This information may be useful for counseling patients who are candidates for EXIT.
